998 related articles for article (PubMed ID: 20142433)
1. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
2. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
3. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
Elife; 2017 Jun; 6():. PubMed ID: 28653623
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S
J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
[TBL] [Abstract][Full Text] [Related]
7. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
8. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
10. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Fiehn O; Showalter MR; Schaner-Tooley CE; ;
Elife; 2016 Feb; 5():. PubMed ID: 26943899
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
[TBL] [Abstract][Full Text] [Related]
13. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
15. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
16. IDH1 and IDH2 mutations in pediatric acute leukemia.
Andersson AK; Miller DW; Lynch JA; Lemoff AS; Cai Z; Pounds SB; Radtke I; Yan B; Schuetz JD; Rubnitz JE; Ribeiro RC; Raimondi SC; Zhang J; Mullighan CG; Shurtleff SA; Schulman BA; Downing JR
Leukemia; 2011 Oct; 25(10):1570-7. PubMed ID: 21647154
[TBL] [Abstract][Full Text] [Related]
17. IDH mutations in acute myeloid leukemia.
Rakheja D; Konoplev S; Medeiros LJ; Chen W
Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
[TBL] [Abstract][Full Text] [Related]
18. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
19. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
20. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
